Ten percent of a 76-patient pivotal trial enrolled within weeks of opening: that pace is the sharpest signal yet that Atsena Therapeutics is not running a typical rare-disease recruitment campaign for ATSN-201, its gene therapy for X-linked retinoschisis. The company dosed its first patient in the Phase 3 cohort of the LIGHTHOUSE trial on June 22, with full enrollment now projected by the end of Q1 2027, topline data in the first half of 2028, and a BLA filing targeted for the second half of that year. For a monogenic disease affecting an estimated 30,000 males across the U.S. and EU, a nine-month enrollment window across North American and European sites is legitimately fast.

The confidence behind that timeline rests on Phase 1/2 results that did something most retinal gene therapy programs cannot claim: structural reversal. The majority of treated patients showed closure of schisis cavities, the abnormal splitting of retinal layers that defines this RS1 mutation-driven disease, alongside meaningful improvements in microperimetry, best-corrected visual acuity, and low-luminance visual acuity. Those gains held through at least one year of follow-up. The Phase 3 primary endpoint, change in microperimetry at 52 weeks, was aligned with both FDA and EMA, which reduces the regulatory interpretation risk that has tripped up other ocular programs at the BLA stage. ATSN-201 also carries RMAT, Fast Track, Rare Pediatric Disease, and Orphan Drug designations from FDA, a combination that compresses review timelines and opens the door to rolling submission.

The delivery mechanism deserves attention independent of the efficacy story. ATSN-201 uses AAV.SPR, a laterally spreading capsid that transduces foveal cones from a subretinal injection placed outside the macula, eliminating the need for surgical foveal detachment. That distinction matters clinically: detachment procedures carry meaningful complication risk, particularly in pediatric patients, and LIGHTHOUSE enrolls children as young as six. A 1:1 randomization with a 12-month delayed-treatment option for the control arm addresses the ethical challenge inherent in placebo-controlled pediatric blindness trials while preserving the clean comparative data regulators require.

The number to watch between now and topline readout is not enrollment speed but the microperimetry effect size at one year in the pivotal cohort. Phase 1/2 responses were described as consistent with FDA approvability, a deliberately precise framing. Whether the Phase 3 data reproduce that threshold in a larger, more heterogeneous population will determine whether Atsena’s 2028 BLA filing becomes a straightforward regulatory conversation or a prolonged one.

Source link: https://www.globenewswire.com/news-release/2026/06/22/3315214/0/en/Atsena-Therapeutics-Doses-First-Patient-and-Reports-Rapid-Early-Enrollment-in-Pivotal-Trial-of-ATSN-201-for-X-Linked-Retinoschisis.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.